Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00043758 · ClinicalTrials.gov registry record · Phase 2

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.

Completed
Registry status
Phase 2
Development phase
170
Enrollment target

NCT00043758: Completed Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.

NCT00043758 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 170 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00043758, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.

COMPLETED
Registry status
Phase 2
Development phase
170 participants
Enrollment target

Study Summary

The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)

Interventions

  • DRUG Tolvaptan

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2002-07
Est. Completion 2004-07
Phase Phase 2

What the finished NCT00043758 record still lists

NCT00043758 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher).

The record links to 0 conditions, and to 1 intervention - of which Tolvaptan is the first listed.

NCT00043758 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00043758 about?

NCT00043758 is a clinical study titled "Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients". The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)

What is the current status of trial NCT00043758?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2002-07. Estimated completion is 2004-07.

What interventions are being tested in trial NCT00043758?

The interventions under investigation include: Tolvaptan (DRUG).

Who is sponsoring clinical trial NCT00043758?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00043758's enrollment target sits among peer trials

170 399th of 2000 higher than 1,598 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02016430 · 170 participants · NA

    Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

  • NCT02621021 · 170 participants · Phase 2

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  • NCT04094701 · 170 participants · NA

    Hip Arthroscopy Postoperative Opioid Demands

  • NCT04166409 · 170 participants · Phase 3

    A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00043758, the US trial registry maintained by the National Library of Medicine. NCT00043758 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.